5010
A. S. Mwakaboko, B. Zwanenburg / Bioorg. Med. Chem. 19 (2011) 5006–5011
recrystallized (di-isopropyl ether) to give 11 as white crystals,
207.8 mg, mp 104 °C; 1H NMR (CDCl3, 300 MHz): d 7.68 (d, 1H,
J = 5.7 Hz, CH@), 7.14 (m, 1H, CH@), 6.48 (m, 1H, OCHO), 6.41 (d,
1H, J = 5.7 Hz, @CH), 2.35 (s, 3H, CH3), 1.99 (s, 3H, CH3). 13C NMR
(CDCl3, 100 MHz): d 173.9 (C@O), 171.5 (C@O), 161.3, 154.1,
143.0, 141.8, 134.1, 117.3, 100.3, 15.2, 10.6; MS [EI m/z, rel. inten-
sity (%)]: 222 ([M]+), 8.9; 223 ([M]++1), 0.1; 126 ([M]+À97,
[C6H5O3]+), 44.5; 97 ([M+À125], [C5H5O2]+), 100); Anal. Calcd for
was purified by column chromatography (hexane/ethyl acetate,
1:1, v/v) to give compound 19 as white crystals, 78.5 mg (14.5%).
An analytical sample was obtained by recrystallization from di-
isopropyl ether, mp 96–99 °C; 1H NMR (CDCl3, 400 MHz): d 6.94
(s, 1H, CH@), 6.24 (s, 1H, OCHO), 5.73 (s, 1H, @CH), 2.30 (s, 2H,
CH2), 2.26 (s, 2H, CH2), 2.02 (s, 3H, CH3), 1.09 (s, 6H, 2 Â CH3).
13C NMR (CDCl3, 100 MHz): d 199.0 (C@O), 172.4 (C@O), 170.5,
141.2, 134.9, 105.1, 95.9, 50.6, 42.1, 32.5, 28.5, 27.9, 10.6; MS [EI
m/z, rel. intensity (%)]: 237 ([M+1]+, 1.0); 236 ([M]+, 8.9); 97
([M+À139], [C5H5O2]+, 100); Anal. Calcd for C13H16O4: C, 66.09; H,
6.83. Found: C, 66.11; H, 6.71%.
Method B. A stirred mixture of 5,5-dimethyl-1,3-cyclohexanedi-
one (18) (300.0 mg, 2.14 mmol), DBU (358.8 mg, 2.36 mmol) and
chloro butenolide 8 (283.9 mg, 2.14 mmol) in dichloromethane
(15 mL) while maintained under nitrogen was set aside at room
temperature for 5 h, until TLC indicated the total consumption of
the chloro butenolide 8. The mixture was processed in the manner
described above. Column chromatography (hexane/ethyl acetate,
2:1, v/v) gave compound 19 as white crystals, 73.3 mg (14%), mp
98–100 °C; 1H NMR (CDCl3, 400 MHz): d 6.94 (s, 1H, CH@), 6.24
(s, 1H, OCHO), 5.73 (s, 1H, @CH), 2.30 (s, 2H, CH2), 2.26 (s, 2H,
CH2), 2.02 (s, 3H, CH3), 1.09 (s, 6H, 2 Â CH3). 13C NMR (CDCl3,
100 MHz): d 199.0 (C@O), 172.4 (C@O), 170.5, 141.2, 134.9,
105.1, 95.9, 50.6, 42.1, 32.5, 28.5, 27.9, 10.6; MS [EI m/z, rel. inten-
sity (%)]: 237 ([M+1]+, 1.0); 236 ([M]+, 8.9); 97 ([M+À139],
[C5H5O2]+, 100); Anal. see above.
C11H10O5: C, 59.46; H, 4.54. Found: C, 59.22; H, 4.41.
3.1.3. 6-Methyl-4-[(4-methyl-5-oxo-2,5-dihydro-2-furanyl)oxy]-
2H-pyran-2-one (13)
Treatment of 4-hydroxy-6-methyl-2H-pyran-2-one (12)
(200.0 mg, 1.59 mmol) with anhydrous potassium carbonate
(241.3 mg, 1.75 mmol) and bromo butenolide
7 (309.0 mg,
2.33 mmol) in dry DMF (4 mL) in the manner described above, fol-
lowed by column chromatography (hexane/ethyl acetate, 2:1, v/v)
gave 13 (121.4 mg, 58.8%). Recrystallization (di-isopropyl ether)
gave an analytically pure sample (107.9 mg) as white crystals,
mp 125–127 °C; 1H NMR (CDCl3, 400 MHz): d 6.97 (s, 1H, CH@),
6.31 (s, 1H, OCHO), 5.84 (s, 1H, CH@CO), 5.77 (s, 1H, CH@C), 2.24
(s, 3H, CH3), 2.02 (s, 3H, CH3). 13C NMR (CDCl3, 100 MHz): d
170.1 (C@O), 167.7 (C@O), 163.8, 163.4, 140.8, 135.3, 99.4, 96.2,
91.5, 20.0, 10.6; MS [EI m/z, rel. intensity (%)]: 222 ([M]+, 7.6);
193 ([M+À29], 2.8, [C10H10O4]+); 97 ([M+À125], [C5H5O2]+, 100);
Anal. Calcd for C11H10O5: C, 59.46; H, 4.54. Found: C, 59.42; H, 4.29.
3.1.4. 4-[(4-Methyl-5-oxo-2,5-dihydro-2-furanyl)oxy]-2H-
chromen-2-one (15)
3.1.7. 3-Methyl-5-[(5-oxotricyclo[5.2.1.02,6]deca-3,8-dien-3-
yl)oxy]-2(5H)-furanone (21)
The reaction of 4-hydroxy-coumarin (14) (400.0 mg,
2.47 mmol) with anhydrous potassium carbonate (412.5 mg,
2.71 mmol) and chloro butenolide 8 (359.6 mg, 2.71 mmol) in
dry DMF (4 mL) was conducted in the manner described above, fol-
lowed by recrystallization from di-isopropyl ether to give 15,
315.4 mg (49.5%) as pure yellowish crystals, mp 177–182 °C; 1H
NMR (CDCl3, 400 MHz): d 7.74–7.27 (m, 4H, ArH protons), 7.11
(m, 1H, CH@), 6.49 (s, 1H, @CHCO), 6.11 (s, 1H, OCHO), 2.09 (s,
3H, CH3). 13C NMR, (CDCl3, 100 MHz): d 170.0 (C@O), 163.0
(C@O), 161.7, 153.4, 140.7, 135.6, 132.9, 124.1, 122.8, 116.9,
114.7, 96.6, 94.2, 10.6; MS [EI m/z, rel. intensity (%)]: 258 ([M]+),
12.9; 259 ([M]++1), 1.9; 97 ([M+À161], [C5H5O2]+, 100); Anal. Calcd
for C14H10O5: C, 65.11; H, 3.90. Found: C, 64.74; H, 3.83.
The tricyclic keto-enol 20 (400.0 mg, 2.47 mmol) was treated
with potassium carbonate (375.4 mg, 2.72 mmol) and chloro bute-
nolide 8 (359.9 mg, 2.72 mmol) in dry DMF (4 mL) at room temper-
ature for 18 h. When TLC indicated total consumption of chloro
butenolide 8, the mixture was treated with ice water (50 mL)
and dichloromethane (20 mL), the separated aqueous layer was ex-
tracted with dichloromethane (2 Â 15 mL), the combined organic
layers washed with brine, dried (Na2SO4) and concentrated in va-
cuo. Column chromatography (hexane/ethyl acetate, 1:1, v/v) of
the resultant material, followed by recrystallization from di-iso-
propyl ether gave 21 (112.6 mg, 18%) as white crystals, mp 168–
171 °C; 1H NMR (CDCl3, 400 MHz): d 6.93 (s, 1H, @CH), 6.13 (s,
1H, OCHO), 6.03 (s, 1H), 5.89 (s, 1H), 5.36 (s, 1H), 3.27 (m, 1H),
3.22 (br s, 1H), 3.02 (br s, 1H), 2.97 (m, 1H), 2.03 (s, 3H, CH3),
1.75 (d, J = 8.5 Hz, 1H), 1.5 (d, J = 8.5 Hz, 1H). 13C NMR (CDCl3,
100 MHz): d 205.4 (C@O), 186.1 (C@O), 170.4, 140.8, 135.2,
133.8, 131.9, 110.3, 97.7, 52.0, 51.3, 46.2, 44.1, 43.6, 10.6; MS [EI
m/z, rel. intensity (%)]: 259 ([M+1]+, 2.0); 258 ([M]+, 13.3); 230
([M+À28], [C14H14O3]+, 3.9); 161 ([M+À97], [C10H9O2]+, 63.3); 97
([M+À161], [C5H5O2]+, 100); Anal. Calcd for C15H14O4: C, 69.76; H,
5.46. Found: C, 69.87; H, 5.28.
3.1.5. 3-Methyl-5-[(3-oxo-1-cyclohexenyl)oxy]-2(5H)-furanone
(17)
Treatment of 1,3-cyclohexanedione (16) (300.0 mg, 2.68 mmol)
with potassium carbonate (407.2 mg, 2.95 mmol) and chloro bute-
nolide 8 (390.3 mg, 2.95 mmol) in dry DMF (3 mL) was conducted
in the manner as described above, to give the desired compound 17
as white crystals, 90.9 mg (16.3%) after column chromatography
(hexane/ethyl acetate, 1:1, v/v). An analytical sample was obtained
by recrystallization from di-isopropyl ether, mp 120–124 °C; 1H
NMR (CDCl3, 400 MHz): d 6.94 (s, 1H, CH@), 6.24 (s, 1H, OCHO),
5.73 (s, 1H, @CH), 2.46–2.28 (m, 6H, 2 Â CH2), 2.01 (s, 3H, CH3).
13C NMR (CDCl3, 100 MHz) d 199.0 (C@O), 174.1 (C@O), 170.5,
141.2, 134.9, 106.3, 95.8, 36.6, 28.2, 20.9, 10.6; MS [EI m/z, rel.
intensity (%)]: 209 ([M+1]+, 2.9); 208 ([M]+, 21.7); 97 ([M+À111],
[C5H5O2]+, 100); Anal. Calcd for C11H12O4: C, 63.45; H, 5.81. Found:
C, 63.26; H, 5.65.
3.2. Bioassays28
3.2.1. Seeds
Seeds of S. hermonthica (from Sorghum bicolor (L.) Moench) were
harvested in the Sudan in 1987. O. cernua seeds were harvested in
Spain in 1994. Seeds were stored in the dark at room temperature
until required.
3.2.2. Preparation of test solutions
3.1.6. 5-[(5,5-Dimethyl-3-oxo-1-cyclohexenyl)oxy]-3-methyl-
2(5H)-furanone (19)
Method A. 5,5-Dimethyl-1,3-cyclohexanedione (18) (300.0 mg,
2.14 mmol) was treated with potassium carbonate (325.8 mg,
2.36 mmol) and chloro butenolide 8 (312.3 mg, 2.36 mmol) in
dry DMF (3 mL) in the manner described above. The crude product
The compounds to be tested were accurately weighed (ca. 1 or
ca. 2 mg) using a 5 decimal balance, dissolved in analytical grade
acetone (1 mL) and then diluted with distilled water to a volume
of 50 mL. Aliquots of these analytical grade solutions were further
diluted with distilled water to obtain test solutions containing 1,
0.1 and 0.01 mg/L test compound and 0.01% (v/v) acetone,